Keros Therapeutics (KROS) Stock Overview
A clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
KROS Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Keros Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.53 |
| 52 Week High | US$69.26 |
| 52 Week Low | US$9.12 |
| Beta | 0.90 |
| 1 Month Change | 26.35% |
| 3 Month Change | 36.61% |
| 1 Year Change | -68.64% |
| 3 Year Change | -57.15% |
| 5 Year Change | -72.60% |
| Change since IPO | 7.22% |
Recent News & Updates
Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%
Nov 18
Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path
Aug 21Recent updates
Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%
Nov 18Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path
Aug 21Shareholders Will Probably Hold Off On Increasing Keros Therapeutics, Inc.'s (NASDAQ:KROS) CEO Compensation For The Time Being
May 29Keros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting Point
May 14Improved Revenues Required Before Keros Therapeutics, Inc. (NASDAQ:KROS) Stock's 44% Jump Looks Justified
May 09Keros Therapeutics: Losing Its Lead Drug Is Bad Medicine
Mar 13Keros Therapeutics: How To Respond To Today's Major Safety Setback And Selloff
Dec 12We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth
Nov 20Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation
Aug 07Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers
Jun 10Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?
Apr 23We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely
Sep 24We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth
Jun 10Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Dec 25Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Sep 08Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07
Aug 04Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Apr 29We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely
Jan 24Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Oct 10We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely
May 05Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?
Mar 13We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate
Jan 19Shareholder Returns
| KROS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 19.0% | -3.1% | 0.07% |
| 1Y | -68.6% | 14.8% | 11.9% |
Return vs Industry: KROS underperformed the US Biotechs industry which returned 16.6% over the past year.
Return vs Market: KROS underperformed the US Market which returned 12.6% over the past year.
Price Volatility
| KROS volatility | |
|---|---|
| KROS Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: KROS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KROS's weekly volatility has decreased from 13% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 82 | Jas Seehra | www.kerostx.com |
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company’s lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases.
Keros Therapeutics, Inc. Fundamentals Summary
| KROS fundamental statistics | |
|---|---|
| Market cap | US$420.18m |
| Earnings (TTM) | US$64.45m |
| Revenue (TTM) | US$246.72m |
Is KROS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KROS income statement (TTM) | |
|---|---|
| Revenue | US$246.72m |
| Cost of Revenue | US$154.96m |
| Gross Profit | US$91.76m |
| Other Expenses | US$27.31m |
| Earnings | US$64.45m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.30 |
| Gross Margin | 37.19% |
| Net Profit Margin | 26.12% |
| Debt/Equity Ratio | 0% |
How did KROS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/10 10:18 |
| End of Day Share Price | 2025/12/09 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Keros Therapeutics, Inc. is covered by 19 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Zemansky | BofA Global Research |
| Corinne Johnson | Goldman Sachs |
| Vamil Divan | Guggenheim Securities, LLC |